Swedish biotech un­veils topline da­ta on weight loss drug de­signed for main­te­nance af­ter GLP-1s

Em­pros Phar­ma’s oral weight loss drug on­ly de­liv­ered an av­er­age 8% body weight re­duc­tion in its Phase IIb test. So it can’t bat­tle with big play­ers with bet­ter da­ta like We­govy and Zep­bound — but the Swedish biotech doesn’t want to com­pete.

In­stead, it’s tar­get­ing peo­ple who want to main­tain their weight loss af­ter tak­ing a GLP-1, and peo­ple who are over­weight or on the low­er end of the obe­si­ty scale.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER